TL-895
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- TL-895
- DrugBank Accession Number
- DB16471
- Background
TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC50 and a Ki of 1.5 nM and 11.9 nM, respectively. TL-895 is under investigation in several clinical trials for its safety and efficacy in various conditions: NCT04419623 (completed, COVID-19 in cancer patients), NCT02825836 (active, not recruiting, B cell malignancies including chronic lymphocytic leukemia), NCT05280509 (recruiting, combination with Ruxolitinib in myelofibrosis), NCT04655118 (recruiting, myelofibrosis), NCT04669067 (active, not recruiting, acute myeloid leukemia with KRT-232), NCT04640532 (recruiting, relapsed/refractory myelofibrosis and JAKi intolerant myelofibrosis with KRT-232), and NCT04878003 (recruiting, Janus kinase inhibitor treatment-naïve myelofibrosis).
- Type
- Small Molecule
- Groups
- Investigational
- Synonyms
- Not Available
- External IDs
- TL-895
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
TL-895 inhibits bruton tyrosine kinase, an enzyme involved in cancer growth.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- 1415823-49-2
- InChI Key
- Not Available
- InChI
- Not Available
- IUPAC Name
- Not Available
- SMILES
- Not Available
References
- General References
- External Link [Link]
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data2 Recruiting Treatment Mastocytosis, Indolent Systemic / Myelofibrosis 1 somestatus stop reason just information to hide 2 Recruiting Treatment Post Polycythemia Vera Myelofibrosis / Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) / Primary Myelofibrosis (PMF) 1 somestatus stop reason just information to hide 1 Completed Treatment Cancer / Carcinoma / Coronavirus Disease 2019 (COVID‑19) / Hematological Malignancy / Solid Tumors 1 somestatus stop reason just information to hide 1, 2 Active Not Recruiting Treatment Acute Myeloid Leukemia 1 somestatus stop reason just information to hide 1, 2 Active Not Recruiting Treatment Chronic Lymphocytic Leukemia / Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma / Relapsed/Refractory B Cell Malignancies / Small Lymphocytic Lymphoma / Treatment-Naive B Cell Malignancies 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
- Not Available
- Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at January 21, 2021 01:43 / Updated at July 20, 2024 09:09